Camlin Fine Sciences Ltd — Capital/Financing Update 2021

Oct 30, 2021

==> picture [100 x 31] intentionally omitted <==

Date: October 30, 2021

||To,
BSE Limited,
25, P. J. Towers,
Dalal Street,
Mumbai – 400 001
Ref:Company Scrip Code: 532834|To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai‐ 400051
Ref:Symbol:CAMLINFINE||Series: EQ|
|---|---|---|

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

This is with reference to our intimations dated June 28, 2018 and June 29, 2018 wherein the Company had informed, inter alia, about the issue of Foreign Currency Convertible Bonds ( FCCBs ) aggregating to US$ 15 Million to International Finance Corporation (“ IFC ”) which are subject to certain anti‐dilution rights and adjustments agreed into between the Company and the IFC.

Further, in accordance with commercial discussion between IFC and the Company and subsequent approval of RBI, certain modifications in the terms of the FCCB Subscription Agreement inter alia change in:

• a. Conversion Kick‐off Price to Rs. 189 per equity share;

• b. Conversion Price to Rs. 105 per equity share;

• c. Coupon offered on FCCBs is interest at the rate of five point five percent (5.5%) per annum on the outstanding amount of IFC FCCBs and in addition to above, compound interest at the rate of one percent (1.0 %) per annum on the outstanding amount of IFC FCCBs.

This is for your information and record please.

For Camlin Fine Sciences Limited

==> picture [55 x 53] intentionally omitted <==

==> picture [106 x 51] intentionally omitted <==

Santosh Parab Chief Financial Officer

==> picture [426 x 57] intentionally omitted <==